A Phase I Multiple Ascending Dose (MAD) Study of RO5458640, a Humanized Monoclonal Antibody Against the TNF-like Weak Inducer of Apoptosis (TWEAK) Ligand, in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Multiple Ascending Dose (MAD) Study of RO5458640, a Humanized Monoclonal Antibody Against the TNF-like Weak Inducer of Apoptosis (TWEAK) Ligand, in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2016

At a glance

  • Drugs RG 7212 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 30 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Planned End Date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top